Main Activity in Nanotechnology
Novavax, Inc. is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on drug delivery and biological technologies.
The Company’s research is focused on developing its technology platforms in drug delivery: micellar nanoparticle (MNP), Novasomes® and Sterisomes®, to enhance the delivery of FDA approved drugs to provide patients with better clinical outcomes. ESTRASORB®, a topical emulsion for estrogen therapy, is its first internally developed FDA-approved topical formulation which uses MNP technology. Novavax also focuses on developing its Virus Like Particle (VLP) technology into vaccines for the prevention of infectious diseases such as HIV/AIDS, pandemic flu, seasonal flu and SARS. Additionally, the biologicals division is developing E-selectin tolerogen in conjunction with the National Institute of Neurological Disorders and Stroke for the prevention of illness where inflammatory and immune responses are involved.
Novavax has a strong commitment to business ethics, and believes that every employee must conduct themselves with honesty, integrity and respect, and in compliance with all applicable laws. To maintain their employment with the company, each employee must be in compliance with the Novavax Code of Business Conduct and Ethics.
Headquartered in Malvern, Pennsylvania, Novavax also maintains additional research facilities in Rockville, Maryland, as well as a 24,000 square foot, state of the art commercial manufacturing facility within Cardinal Health’s Philadelphia, Pennsylvania complex.
508 Lapp Road